Prognostic and Immunological Potential of Ribonucleotide Reductase Subunits in Liver Cancer

Figure 4

Mutation patterns and coexpression analyses of RR subunits. (a) Summary genetic alterations of RRM1, RRM2, and RRM2B in TCGA-LIHC (). (b) Frequency of different somatic alterations of RRM1, RRM2, and RRM2B in TCGA-LIHC. (c) Coexpression matrix of RRM1, RRM2, and RRM2B. (d) Interaction gene networks of RRM1, RRM2, and RRM2B, such as glutaredoxin (GLRX), thioredoxin (TXN), chromosome segregation 1-like (CSE1L), transcription factor binding to IGHM enhancer 3 (TFE3), adenylate kinase 1 (AK1), E2F transcription factor 3 (E2F3), cytidine/uridine monophosphate kinase 1 (CMPK1), isocitrate dehydrogenase (NAD(+)) 3 catalytic subunit alpha (IDH3A), thioredoxin reductase 1 (TXNRD1), guanylate kinase 1 (GUK1), E2F transcription factor 6 (E2F6), peptidylprolyl isomerase B (PPIB), coenzyme Q7, hydroxylase (COQ7), diphthamide biosynthesis 1 (DPH1), (polo-like kinase 1) PLK1, AT-rich interaction domain 2 (ARID2), MCM4, minichromosome maintenance complex component 5 (MCM5), WD repeat domain 43 (WDR43), and cyclin-dependent kinase inhibitor 2A (CDKN2A).

(a)

(b)

(c)

(d)